When SURMOUNT-1 was published in 2022, it did something no approved obesity drug had done in a phase 3 trial: it pushed average weight loss into the range once reserved for bariatric surgery. The trial established tirzepatide — sold as Zepbound for weight management and Mounjaro for diabetes — as the most effective medication yet approved for obesity. Here is what it actually tested, what it found, and where its evidence stops.
Why it mattered
Tirzepatide is a dual agonist: it activates both the GIP and GLP-1 receptors, where semaglutide acts on GLP-1 alone. The open question going in was whether that dual mechanism would translate into larger weight loss in people with obesity but without diabetes. SURMOUNT-1 was the pivotal phase 3 trial designed to answer it, and its result reset expectations for how much an injectable medication could achieve. For how that mechanism stacks up against single-agonist therapy, see our read of the tirzepatide-versus-semaglutide evidence.
The design
SURMOUNT-1 was a phase 3, double-blind, randomized, placebo-controlled trial. It enrolled 2,539 adults with a BMI of 30 or more — or 27 or more with at least one weight-related complication — and excluded people with diabetes. Participants were assigned in a 1:1:1:1 ratio to once-weekly subcutaneous tirzepatide at 5, 10, or 15 mg, or to placebo, for 72 weeks, which included a 20-week dose-escalation period. Everyone also received lifestyle counseling. At baseline the mean body weight was 104.8 kg and the mean BMI was 38.0. The coprimary endpoints were the percentage change in weight and the proportion achieving a weight reduction of at least 5%.[1]
The primary result
At week 72, the mean change in body weight was −15.0% with 5 mg, −19.5% with 10 mg, and −20.9% with 15 mg, against −3.1% with placebo — every comparison highly significant.[1] The threshold analyses tell the same story from another angle: the share of participants losing at least 5% of body weight was 85%, 89%, and 91% across the three doses versus 35% on placebo. On the two higher doses, 50% (10 mg) and 57% (15 mg) of participants lost 20% or more of their starting weight, compared with just 3% on placebo.[1] Reductions of that size in a drug trial were, until recently, essentially unheard of.
Key secondary measures
Weight was not the only thing that moved. The trial reported improvements across all prespecified cardiometabolic measures with tirzepatide — the domains such trials track include waist circumference, blood pressure, lipids, and glycemic markers — consistent with the drug's metabolic reach beyond the scale.[1] One caveat that these averages hide: some of the weight lost on GLP-1-class drugs is lean mass, not only fat, which is why body composition and strength deserve their own attention. We cover that in detail in GLP-1 drugs and muscle or lean-mass loss.
Safety
The most common adverse events with tirzepatide were gastrointestinal — nausea, diarrhea, constipation, vomiting — and most were mild to moderate, occurring primarily during the dose-escalation phase.[1] Adverse events led to treatment discontinuation in 4.3%, 7.1%, and 6.2% of the 5-, 10-, and 15-mg groups, respectively, versus 2.6% on placebo — a modest gap that is worth weighing against the size of the benefit.[1]
The honest limitations
SURMOUNT-1 is a strong efficacy trial, but it is a specific one. It studied adults with obesity and no diabetes, so its numbers do not automatically transfer to people with type 2 diabetes, in whom weight loss on incretin drugs tends to be smaller. It paired the drug with lifestyle counseling, so the reported effect is medication plus support, not medication alone. Critically, this trial reported no cardiovascular-outcome data and no long-term follow-up — it measured weight and cardiometabolic markers over 72 weeks, not heart attacks, strokes, or survival. And the weight loss is durable only while treatment continues: a separate maintenance trial, SURMOUNT-4, found that participants switched from tirzepatide to placebo regained a substantial share of the weight they had lost, while those who stayed on the drug kept it off.[3] For the parallel evidence in the GLP-1-only class, our summary of the semaglutide weight-loss trials — including STEP 1[2] — makes the same point about rebound after stopping.
The bottom line: SURMOUNT-1 shows that tirzepatide produces the largest average weight loss of any approved obesity medication in a well-run trial — but it is one trial, in one population, over 72 weeks, and obesity is a chronic condition that returns when treatment ends. This is a summary of the evidence, not medical advice; decisions about any of these drugs belong with a clinician who knows your history.